Clinical Trial Update: Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia [Phase 1, Phase 2]

View source ↗

Summary

The trial update reports tolerability and preliminary efficacy data for intravenous infusion of autologous mesenchymal stem cells (MSC_Apceth) in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Artery Disease

Drugs mentioned

• MSC_Apceth (autologous mesenchymal stem cells)

Snippet

Sponsor: Apceth GmbH & Co. KG | Conditions: Critical Limb Ischemia, Peripheral Artery Disease | Phase 1, Phase 2 | Status: COMPLETED